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Abstract 
Background:An audit trial was conducted to 
review our practice of Universal GBS screening for 
our pregnant patients and its effect on fetal outcome. 
Methods: In  this descriptive study  all the patients 
attending antenatal clinic had their GBS swab 
performed between 35-37 weeks of pregnancy. 
Patients were informed about their GBS status on 
next visit and advised to attend early in labour or in 
case of rupture of membranes for administration of 
intra-partum antibiotic prophylaxis. One dose of 
Benzathine Penicillin  3 mu within  2 hours of 
delivery to reduce the risk of early onset Group B 
Streptococcus agalactiae infection. Blood cultures 
were drawn in all the babies with GBS positive 
mothers. The cost effectiveness of the screening and 
treatment were studied by checking for the cost 
according to the hospital stores department of swab, 
culture and cost of medication to the patients during 
this period. 
Results: There was a total of 2405 deliveries during 
this period. Two hundred and nine cases were GBS 
positive. Intrapartum antibiotic prophylaxis [IAP] 
was given to 48 patients while 161 did not receive 
any treatment. All the babies had no growth on 
blood culture. 
Conclusion: The cost involved in the GBS swab, 
culture and its treatment clearly indicate that the 
practice is not cost effective. In view of our audit we 
have to reconsider our practice of universal 
screening changed to high risk patient screening 
only. 




    Group B streptococcus (Streptococcus 
agalactiae)(GBS) is considered as afrequent cause of 
severe early onset (EOGBS) (at less than 7 days of age) 
infection in newborn infants with increased fetal 
morbidity and mortality.1,2 There has been controversy 
regarding prevention of GBS. While in U.S.A and 
Canada there is universal screening for GBS. In U.K 
there is screening for high risk patients only .On 
comparison there is not much difference in the 
incidence of EOGBS in both countries which is 
0.5/1000 births while the vaginal carrier state which is 
around 25% is comparable in these communities.3,4 
    The Cochrane Database of Systematic Reviews, 
DARE, EMBASE, Medline and PubMed(electronic 
databases) were searched for relevant randomised 
controlled trials, systematic reviews and meta 
analysis.5,6 The search was restricted to articles 
published between 2003 and August 2011 concluded 
that, while intra-partum antibiotic prophylaxis ( IAP) 
for colonized mothers reduced the incidence of EOGBS 
disease, it has not been shown to reduce mortality or 
GBS-related mortality. Routine antenatal screening 
and treatment have disadvantages for the mother and 
baby. These include anaphylaxis, increased medication 
during labour and the neonatal period, and possible 
infection with antibiotic-resistant organisms, 
particularly when broad spectrum antibiotics such as 
amoxicillin are used for prophylaxis. 
    Group B streptococcus (Streptococcus agalactiae) is 
recognized as the most frequent cause of severe early 
onset (less than seven days of age) infection in 
newborn infants. A survey in 2001 demonstrated that 
less than 1% of UK maternity units were performing 
systematic screening for GBS and, so far, UK clinicians 
have not generally adopted guidelines from the USA, 
Australia and Canada that encourage screening.7,8        
  The US Centers for Disease Control and Prevention 
(CDC) now recommend that all pregnant women 
undergo bacteriological screening, with vaginal and 
rectal swabs taken for GBS culture at 35–37 weeks of 
gestation.9,10             The UK National Screening 
Committee examined the issue of strategies for the 
prevention of EOGBS disease in November 2008 and 
recommended that routine screening using 
bacteriological culture or near-patient testing 
techniques should not be introduced into UK 
practice.11,12 
 
Patients and Methods  
    In  this descriptive study  patients who had attended 
the labor ward at Tawam Hospital, were included. The 
Journal of Rawalpindi Medical College (JRMC); 2014;18(2):274-277 
 275 
inclusion criteria were all antenatal patients who 
presented in labor during the period between April 
2009 till October 2009. All the patients attending 
antenatal clinic had their GBS swab performed 
between 35-37 weeks of pregnancy. Patients were 
informed about their GBS status on next visit and 
advised to attend early in labour or in case of rupture 
of membranes for administration of intra-partum 
antibiotic prophylaxis. One dose of Benzathine 
Penicillin  3 mu within  2 hours of delivery to reduce 
the risk of early onset Group B Streptococcus 
agalactiae infection. Blood cultures were drawn in all 
the babies with GBS positive mothers. The cost 
effectiveness of the screening and treatment were 
studied by checking for the cost according to the 
hospital stores department of swab, culture and cost of 
medication to the patients during this period. 
Results 
     Total number of deliveries was 2405 and GBS 
positive mothers was 209. The carrier state of GBS in 
pregnant patients in this time period was 9%. When 
considering the patients who were treated with IAP it 
is important to note that the majority were untreated 
in all these months. Only 48(23%) patients received 
treatment with IAP, while 161(77%) patients did not 
receive any IAP which is 77%(Table 1). When Blood 
culture was performed on the babies of these GBS 
positive mothers irrespective of the fact whether they 
had received IAP or not, none of the babies had a 
culture growth positive for GBS. 

























APRIL 385 38 6 32 16% 84% 0 
MAY 374 28 7 21 25% 75% 0 
JUNE 378 29 5 24 17% 83% 0 
JULY 430 45 11 34 24% 76% 0 
AUGU
-ST 371 43 14 29 33% 67% 
0 
SEPTE
-MBER 396 25 5 20 20% 80% 
0 
OCTO-
BER 71 1 0 1 - - 
0 
TOTAL 2405 209 48 161 23% 77% 
0 
 
      
     Maximum number of GBS positive patients who 
delivered were 45 in the month of July while minimum 
was 1 in the month of October. The maximum number 
of 14 patients was treated for GBS with IAP were in 
the month of August, while minimum number of 5 
patients was treated for GBS with IAP in the month of 
June .The overall patients who received IAP was 32% 
 (Table 2).  
Table 2: Group B Streptococcus during 
pregnancy and intra-partum antibiotic 
prophylaxis 
  Month Total GBS 
+ patients 
Treated Untreated 
April 38 06 32 
May 28 07 21 
June 29 05 24 
July 45 11 34 
August 43 14 29 
September 25 05 20 
October 01 0 01 
Total 209 48(23%) 161(77%) 
 
    To check for the cost effectiveness of our policy we 
requested the price list from our medical stores .As per 
Stores Department Tawam Hospital 2009 . Cost of this 
prophylaxis per patients was 176.0 Dhs per patient 
(Table 3) 
 
Table 3: Intrapartum antibiotic prophylaxis- 
cost incurred 
• Pen G 5mu      =Dhs 5/ 
• Pen G2.5mu    =Dhs 2.5/ 
• Normal Saline 100mls    = Dhs3.7/ 
• Normal Saline 50mls     =Dhs3.7/ 
• Vent Flow        =Dhs2.47/ 
• IV set               =Dhs21.01/ 
• Opsite              =Dhs1.67/ 
• GBS swab              =Dhs 1.10/ 
• Culture testing       =Dhs10.0/ 
TOTAL USED PER PATIENT=Dhs175.9 ( Dhs 
176.00) 
-  6th April 2009 till 6th October 2009 
Cost of GBS swab and culture of   Dhs 11.10/=     
2405 patients x 1.10 x10 =  Dhs  26,455 /= 
Cost of treatment Dhs 40.05/=        48 patients x 
40.05= Dhs 1922.4/= 
Total cost  26,455 + 1922.4= 28,377.4/  
 
Discussion 
                       CDC recommendation is to  screen  all the pregnant 
females for GBS attending antenatal clinic. Their GBS 
swab should be performed between 35 – 37 weeks of 
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pregnancy. Ideally patients with GBS positive status 
should receive at least one dose of   Benzathine 
penicillin 3 mu within 2 hours of delivery to reduce 
the risk of EOGBS.. In patients who are carrier for GBS 
the transmission rate is not 100%.The risk of EOGBS is 
reduced by the administration of IAP  15,16 
                      Present  audit has clearly shown that the carrier rate 
for GBS is around 9% which is one third of the 
incidence in the U.K and U.S.A which is nearly 
25%.12,13 Therefore the recommendation of CDC might 
not hold true for our community. Considering the fact 
that we are spending such a large amount of our 
resources on screening of a condition which is not as 
prevalent as in the developed countries is an eye 
opener and these funds can be used in other research, 
screening and treatment strategies of diseases which 
are more prevalent in our community. 
     The main limitation of our study was the fact that 
although all the patients were screened for GBS only 
23% of the total positive patients received IAP.  We 
need to review and study the factors and reasons for 
the low rate of administration of the IAP in our 
patients.The effectiveness of any screening test 
according to the WHO definition depends on the 
uptake of the test, the prevalence of the disease in the 
community and treating the positive cases to prevent 
disease. 
The CC1 Conference on Preventive Aspects of Chronic 
Disease, held in 1951, defined screening as "the 
presumptive identification of unrecognized disease or 
defect by the application of tests,  examinations , or 
other procedures which can be applied rapidly. 
Screening tests sort out apparently well persons who 
probably have a disease from those who probably do 
not. A screening test is not intended to be diagnostic. 
Persons with positive or suspicious findings must be 
referred to their physicians for diagnosis and 
necessary treatment. 16,17 
The audit has shown that there were no babies with 
positive GBS culture even though mothers were 
positive for GBS and less than 50% of these patients 
received treatment. For an effective screening 
programme all test positive patients should be given to 
all those patients   
     The RCOG guideline for the prevention of EOGBS 
advises the use of selective screening for GBS. The 
guideline has specific criteria for including patients for 
the GBS screening and prophylaxis. 18 These include 
1. Patients with a previously affected baby with 
EOGBS septicemia. If GBS was detected in a previous 
pregnancy, the likelihood of carriage in a subsequent 
pregnancy is around 38%.This gives a risk estimate of 
neonatal EOGBS disease of approximately 0.9 
cases/1000 births versus a background risk of 0.5 
cases/1000 births or 2.3 cases/1000 births in women 
with GBS detected in the current pregnancy. The time 
interval between the two pregnancies and the intensity 
of colonisation in the previous pregnancy are 
predictive of recurrent GBS colonisation.18 
2.GBS bacteuria anytime in this current pregnancy 
GBS bacteriuria is associated with a higher risk of 
chorioamnionitis  and neonatal disease.19,20 It is not 
possible to accurately quantify these increased risks. 
These women should be offered IAP. Women with 
GBS urinary tract infection (growth of greater than 105 
cfu/ml) during pregnancy should receive appropriate 
treatment at the time of diagnosis as well as IAP. 
3. Intrapartum fever >38*c 
4. Prolonged rupture of membranes > 18 hrs 
5. Prematurity <37 weeks and <35 weeks 
     Keeping the above criteria we can introduce a 
policy of selective screening for GBS  in our hospital. 
This will make it more cost effective without 
increasing patient morbidity and mortality. The 
incidence of EOGBS disease in the UK in the absence 
of systematic screening or widespread intra partum 
antibiotic prophylaxis (IAP) is 0.5/1000 births, 
which is similar to that seen in the USA after 
universal screening and IAP, despite comparable 
vaginal carriage rates.19 
 
Conclusion 
1. As compared to developed world,  there is a 
low carrier rate of GBS in developing world. 
2. The treatment of screened positive patients is 
inadequate in our set up. 
3. Selective screening and treatment of GBS in 
high risk patients is advisable  
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